EMA Recommends First Veterinary Vaccine Using Self-Amplifying RNA Technology for Cat Protection
核心洞察
The European Medicines Agency (搜索) has recommended marketing authorization for Nobivac NXT HCPChFeLV (搜索), marking the first veterinary vaccine in the EU to utilize self-amplifying RNA technology.
The vaccine provides comprehensive protection against five major feline pathogens including feline herpesvirus, calicivirus, panleucopenia virus, leukaemia virus, and Chlamydia felis (搜索).
Clinical studies involving 142 cats demonstrated adequate immune responses with immunity beginning one week after vaccination and lasting up to three years for certain pathogens.
The European Medicines Agency (搜索) (EMA) has recommended granting marketing authorization for Nobivac NXT HCPChFeLV (搜索), a groundbreaking veterinary vaccine that represents the first EU-approved feline vaccine incorporating self-amplifying RNA technology. This innovative vaccine targets five major pathogens responsible for common infectious diseases in cats.
Comprehensive Pathogen Coverage
The vaccine provides protection against a broad spectrum of feline diseases by targeting five critical pathogens. These include feline herpesvirus type 1 (搜索), which causes highly contagious upper respiratory tract and eye diseases, and feline calicivirus (搜索), responsible for contagious respiratory and oral infections. The vaccine also protects against feline panleucopenia virus (搜索), a potentially fatal pathogen that can cause diarrhea, vomiting, fever, and lethargy, particularly dangerous in kittens.
Additionally, the vaccine addresses feline leukaemia virus (搜索), which suppresses the immune system and commonly causes cancer in cats, and Chlamydia felis (搜索), a bacterium primarily responsible for eye infections.
Innovative RNA Technology
The vaccine employs a dual-technology approach combining traditional attenuated viral strains with cutting-edge self-amplifying RNA technology. For four pathogens, it contains live attenuated strains of feline herpesvirus type 1 (搜索) (G2620A), feline calicivirus (搜索) (F9), feline panleucopenia (MW-1), and Chlamydia felis (搜索) (Baker). These weakened strains stimulate immune responses and help the body recognize and mount rapid responses to future pathogen exposure.
For feline leukaemia virus (搜索) protection, the vaccine utilizes self-amplifying RNA packaged in replication-deficient viral replicon particles. This RNA vector technology enables the particle to deliver RNA to cells, where it reproduces temporarily and to a limited extent, enabling production of feline leukaemia virus proteins that trigger protective immune responses.
Clinical Efficacy and Safety Profile
The EMA's veterinary medicines committee (CVMP) evaluated comprehensive safety and efficacy data from 15 controlled studies and one field study involving 142 cats under normal everyday conditions. The studies demonstrated that the vaccine triggers adequate immune responses against all five pathogens, with immunity beginning approximately one week after vaccination.
The duration of protection varies by pathogen, providing three years of immunity for feline panleucopenia virus (搜索) and one year for the remaining four pathogens following primary immunization.
Clinical Benefits and Tolerability
Clinical studies revealed significant benefits across all targeted pathogens. The vaccine reduces mortality, clinical signs of feline herpesvirus type 1 (搜索) infection, and viral shedding. For feline calicivirus (搜索), it decreases clinical signs and viral shedding, while completely preventing mortality, clinical signs, leucopenia, and viral shedding from feline panleucopenia virus (搜索) infection.
The vaccine also reduces clinical signs and bacterial shedding from Chlamydia felis (搜索) infection and decreases clinical signs and viraemia associated with feline leukaemia virus (搜索).
The vaccine demonstrates good tolerability, with the most common side effects occurring in 1 to 10 out of 100 treated cats. These include swelling at the injection site and elevated body temperature, both typically lasting about one day and considered typical vaccine reactions.
Regulatory Pathway and Manufacturing Standards
The CVMP concluded that the benefits of Nobivac NXT HCPChFeLV (搜索) outweigh its risks, considering the vaccine safe for both the administering person and the environment when used according to the summary of product characteristics. The manufacturing process and final batch testing meet requirements to ensure consistent vaccine quality.
The committee's recommendation will now proceed to the European Commission, which will issue a legally binding EU-wide authorization decision for this pioneering veterinary vaccine technology.